RDGL
Vivos Inc. [RDGL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RDGL Stock Summary
Top 10 Correlated ETFs
RDGL
Top 10 Correlated Stocks
RDGL
In the News
RDGL Financial details
Company Rating
-
Market Cap
40.7M
Income
-3.39M
Revenue
19.5K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
13.21
Forward P/E
-
PEG
3.96
P/S
1078.43
P/B
18.41
P/C
-
P/FCF
-25.22
Quick Ratio
14.39
Current Ratio
14.59
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.01
EPS next Y
-
EPS next Q
-
EPS this Y
13.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.13%
Revenue last 5Y
15.47%
Revenue Q/Q
-
EPS Q/Q
61.11%
-
-
-
-
SMA20
-
SMA50
50%
SMA100
-29.41%
Inst Own
-
Inst Trans
-
ROA
130%
ROE
131%
ROC
-1.75%
Gross Margin
-5%
Oper. Margin
-9831%
Profit Margin
7820%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.04119-0.1195
52W High
-
52W Low
-
RSI
48.35
Rel Volume
0.6
Avg Volume
680.86K
Volume
409K
Perf Week
9.01%
Perf Month
-8.33%
Perf Quarter
-16.84%
Perf Half Y
-1.63%
-
-
-
-
Beta
1.493
-
-
Volatility
0%, 0.01%
Prev Close
0.83%
Price
0.121
Change
-3.2%
Company Profile
- Volume Average 680.86K
- Market Capitalization 40.7M
- Employee 1
- CEO Dr. Michael K. Korenko Ph.D.
- Headquarters Richland,WA,US
- IPO Date 1998-09-02
-
Website
https://www.radiogel.com 
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
